Leucovorin (Folinic Acid)

Folinic Acid, the active ingredient in Leucovorin, is a folate analog presented as a sterile solution for epidural, intrabursal, and intracoronary administration. It is used to mitigate toxicity of antifolate chemotherapy and to treat folate deficiency. GNH USA supplies Leucovorin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Leucovorin is employed in clinical settings where folate pathways are compromised or need support during chemotherapy. - Methotrexate toxicity: provides rescue therapy that reduces cellular damage caused by methotrexate overdose. - 5‑Fluorouracil‑based chemotherapy: enhances efficacy and reduces toxicity when given as an adjunct. - Folate deficiency: restores normal folate levels in patients with inadequate dietary intake or malabsorption.

Leucovorin may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after administration. - Diarrhea: loose stools that resolve with continued therapy. - Rash: transient skin erythema or itching. - Fever: low‑grade temperature elevation. - Headache: mild discomfort not requiring intervention.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Acute renal failure: sudden loss of kidney function. - Severe neutropenia: marked drop in white blood cells increasing infection risk. - Thromboembolic events: blood clots in veins or arteries.

Before using Leucovorin, clinicians should evaluate patient history and monitor for specific risks. - Renal impairment: adjust dosing or monitor renal function closely. - Hepatic disease: assess liver enzymes and consider dose modification. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Breastfeeding: weigh benefits against possible infant exposure through milk. - Concomitant chemotherapy: coordinate timing to avoid antagonism of anticancer effect. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Leucovorin can influence the activity of several co‑administered drugs.

Major Interactions (Avoid): - High‑dose methotrexate: may reduce therapeutic efficacy if given simultaneously. - Antifolate agents other than methotrexate: can diminish intended cytotoxic effect.

Moderate Interactions (Monitor Closely): - Trimethoprim‑sulfamethoxazole: may increase risk of hematologic toxicity. - Phenytoin: possible alteration of folate metabolism requiring monitoring. - Vitamin B12 deficiency: concurrent deficiency may blunt response, necessitating supplementation.